CURN.SW CURATIS N AG
- Market cap
- CHF 90.6M
- P/E
- -
- P/B
- 1.86x
- ROE
- -3.3%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CURN.SW undervalued?
Graham numberThe Graham number of CURATIS N AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CURATIS N AG fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-3.3%), below 10%.
ROA 0/1
Return on assets (-2.8%) is below the industry median (3.7%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (81.0%) is above the industry median (24.7%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.9x) is below the industry median (2.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
CURATIS N AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnosti…
Full company profileCURATIS N AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CURATIS N AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.9M | 17.6M | 16.2M | 17.3M | 4.11M | 0.00 | 0.00 | 0.00 | 6.90M | 10.8M | 31.8M |
| Gross Profit | 1.98M | 2.00M | 1.62M | 552K | 172K | 0.00 | -1.52M | 0.00 | 1.59M | 2.84M | 992K |
| Operating Income | -508K | -705K | -765K | -861K | -559K | -410K | -5.18M | -16.3M | -3.25M | -1.55M | -1.60M |
| EBITDA | -625K | -120K | -741K | -862K | 8.00K | -130K | -38.4M | -38.3M | -4.34M | -1.13M | -836K |
| Net Income | -1.02M | -516K | -762K | -940K | -16.0K | 137K | -34.7M | -49.4M | -4.35M | -1.42M | -1.63M |
| EPS | -0.01 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | -222 | -176 | -1.49 | -0.28 | -0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 7.09M | 6.69M | 2.19M | 2.17M | 127K | 136K | 14.0M | 120K | 55.5M | 56.0M | 57.9M |
| Total Liabilities | 2.05M | 2.01M | 1.81M | 2.73M | 384K | 536K | 7.29M | 432K | 9.94M | 9.88M | 9.11M |
| Shareholders' Equity | 5.04M | 4.68M | 377K | -552K | -257K | -400K | 6.75M | -312K | 45.6M | 46.1M | 48.8M |
| Cash & Short-term Investments | 975K | 1.55M | 943K | 880K | 63.0K | 124K | 1.34M | 9.00K | 3.01M | 1.87M | 3.60M |
| Total Debt | 242K | 230K | 366K | 1.01M | 280K | 429K | 3.00M | 133K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -77.0K | 124K | -749K | -662K | -378K | -359K | -4.65M | -1.89M | -825K | -1.31M | -3.55M |
| Capital Expenditure | 8.00K | 13.0K | 4.00K | 0.00 | 0.00 | 0.00 | 4.00K | 0.00 | 0.00 | 1.22M | 0.00 |
| Free Cash Flow | -85.0K | 111K | -753K | -662K | -378K | -359K | -4.66M | -1.89M | -825K | -2.53M | -3.55M |
| Ratios | |||||||||||
| ROE | -20.2% | -11.0% | -202.1% | - | - | - | -514.3% | - | -9.5% | -3.1% | -3.3% |
| ROA | -14.3% | -7.7% | -34.8% | -43.2% | -12.6% | 100.7% | -247.3% | -41,150.0% | -7.8% | -2.5% | -2.8% |
| Net Profit Margin | -5.7% | -2.9% | -4.7% | -5.4% | -0.4% | - | - | - | -63.0% | -13.1% | -5.1% |
| Debt to Equity | 0.05x | 0.05x | 0.97x | - | - | - | 0.44x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CURATIS N AG dividends
CURATIS N AG has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4480 on Apr 26, 2024.
Who owns CURATIS N AG
- Insiders 77.91%
- Institutions 0.87%
- Public & others 21.22%
- Shares outstanding 5.31M
- Free float 1.15M
CURATIS N AG company profile
- Company name
- CURATIS N AG
- Ticker
- CURN.SW
- ISIN
- CH1330780979
- Exchange
- SIX Swiss Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 9
- Fiscal year end
- December
- Address
- Weierweg 7, Liestal, Switzerland, 4410
- Phone
- 41 61 927 8777
- Website
- curatis.com
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/intersticial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophtalmic/ antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with huntington's disease, and antiepileptic. The company also develops C-PTBE-01, which is in Phase IIb clinical trial for the treatment of peritumoral brain edema; C-AM-01 that is in Phase IIa clinical trial for the prevention of severe migraine with aura; C-MOH-01, which is in Phase IIa clinical trial for the treatment and prevention of medication overuse headache; and C-FI-01 that is in phase I clinical trial for the treatment of fibrotic or inflammatory orphan or ultra-orphan diseases. The company was founded in 2002 and is based in Liestal, Switzerland.
CURATIS N AG management
6- Dr. Roland RutschmannCEO & Executive Director · born 1962
- Mr. Gunter GraubachFounder, Executive Director & Chief Corporate Development Officer · born 1964
- Mr. Patrick RamsauerChief Financial Officer
- Mr. Francois BersierChief Operating Officer
- Dr. Kirsty Crame M.D.Chief Medical Officer
- Mr. Timm Trenktrog Ph.D.Head of Chemistry, Manufacturing and Controls